SCHEMBL3495162

SCHEMBL3495162

CC(C)N1C(=O)C(C)(C)Oc2cc(Nc3ncc(C#N)c(NC4CC(C)(C)NC(C)(C)C4)n3)ccc21

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTK2 Q05397 2/20 0.36
PTK2B Q14289 1/20 0.36
SLC2A1 P11166 1/20 0.36
PRKCQ Q04759 2/20 0.35
SYK P43405 3/20 0.35
PKMYT1 Q99640 2/20 0.35
LRRK2 Q5S007 5/20 0.35
SLC9A1 P19634 1/20 0.35
CSF1R P07333 2/20 0.34
CSNK2A2 P19784 1/20 0.34
CSNK2A1 P68400 1/20 0.34
CDK4 P11802 1/20 0.34
CDK6 Q00534 1/20 0.34
ULK1 O75385 1/20 0.34
PRKCD Q05655 1/20 0.34
AURKA O14965 2/20 0.34
JAK3 P52333 2/20 0.34
DAPK3 O43293 1/20 0.34
JAK2 O60674 1/20 0.34
PRKD3 O94806 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3496385 0.91 SLC2A1 (0.37) PTK2PTK2BSLC2A1PRKCQSYK
SCHEMBL3496173 0.88 LRRK2 (0.41) PTK2PTK2BSLC2A1PRKCQSYK
SCHEMBL3497097 0.87 PRKCQ (0.37) PTK2PTK2BSLC2A1PRKCQSYK
SCHEMBL3497196 0.79 PRKCQ (0.47) PTK2PTK2BPRKCQSYKLRRK2
SCHEMBL3496014 0.79 LRRK2 (0.40) PTK2PTK2BSLC2A1PRKCQSYK
SCHEMBL3496532 0.79 SYK (0.41) PTK2PTK2BSLC2A1PRKCQSYK
SCHEMBL3496215 0.79 CHEK1 (0.37) PTK2PTK2BPRKCQSYKLRRK2
SCHEMBL3495251 0.78 PRKCQ (0.37) PTK2PTK2BSLC2A1PRKCQSYK
SCHEMBL3495540 0.77 PRKCQ (0.37) PTK2PTK2BSLC2A1PRKCQSYK
SCHEMBL1741179 0.75 SYK (0.45) PTK2PTK2BPRKCQSYKLRRK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100130486-A1 CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS RIGEL PHARMACEUTICALS, INC. 2010-05-27 US claimed
US-8993585-B2 Cyclic amine substituted pyrimidinediamines as PKC inhibitors RIGEL PHARMACEUTICALS, INC. (US) 2015-03-31 US disclosed
US-20100130486-A1 CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS RIGEL PHARMACEUTICALS, INC. 2010-05-27 US disclosed
EP-2183225-A1 CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS Rigel Pharmaceuticals, Inc. (US) 2010-05-12 EP disclosed
WO-2009012421-A1 CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS RIGEL PHARMACEUTICALS, INC. (US) 2009-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130486-A1 CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS PRKCH, PKD2, PRKCQ PTK2 513/4885PTK2B 160/4885SLC2A1 4131/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.